ASCEMBL Safety, Discontinuations, and 48-Week Follow-up

Dr Jabbour discusses updates from the 2021 ASH Annual Meeting and Exposition in chronic myeloid leukemia, including findings from the phase 3 ASCEMBL trial (NCT03106779) evaluating asciminib (Scemblix) vs bosutinib (Bosulif) and data with ponatinib (Iclusig) from a post hoc analysis of the phase 2 OPTIC trial (NCT02467270).